Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation
Yıl: 2019 Cilt: 30 Sayı: 2 Sayfa Aralığı: 122 - 131 Metin Dili: İngilizce İndeks Tarihi: 20-05-2019
Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation
Öz: The gastrointestinal (GI) system is one of the most commonly affected sites during a hematopoietic stem cell transplantation (HSCT)due to toxicities of preparative regimens, the accompanying immunodeficiency, and organ damage caused by graft versus host disease.In this review, we focus on early GI and liver complications following autologous (auto-) and allogeneic (allo-) HSCT and clarify both therisk factors and therapeutic strategies. Early GI and liver complications associated with HSCT remain challenging issues. Despite theimprovements in this field during the last decade, treatments for these complications still place a significant burden on both patientsand the physicians treating these patients. GI and liver complications remain some of the causes of mortality associated with HSCT. Forpracticing hematologists, oncologists, and gastroenterologists in this field, the awareness and early diagnosis of the GI complicationsremain important factors to obtain optimal outcomes in this patient population.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011; 1: e16. [CrossRef]
- Pedrazzoli P, Ferrante P, Kulekci A, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003; 32: 489-94. [CrossRef]
- Pedrazzoli P, Ledermann JA, Lotz JP, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006; 17: 1479-88. [CrossRef]
- Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An Overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother 2016; 22: 505-14. [CrossRef]
- Demirer T, Buckner CD, Appelbaum FR, et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769-74.
- Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966; 62: 21-78.
- Tuncer H, Rana N, Milani C, et al. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol 2012; 18: 1851-60. [CrossRef]
- Giorgi U D, Wandt H, Lioure B, et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors. The experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working party. Bone Marrow Transplant 2004; 34: 1033-7. [CrossRef]
- Rodrigues FG, Dasilva G, Wener SD. Neutropenic enterocolitis. World J Gastroenterol 2017; 23: 42-7. [CrossRef]
- Chaudhry HM, Bruce AJ, Wolf RC, et al. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biol Blood Marrow Transplant 2016; 22: 605-16. [CrossRef]
- Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National institutes of Health consensus Development project on criteria for clinical Trials in chronic Graft-versus-Host Disease: preface to the series. Biol Blood Marrow Transplant 2015; 21: 387-8. [CrossRef]
- Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
- Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214-9. [CrossRef]
- McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and liver. Blood 2016; 127: 1544-50. [CrossRef]
- Simms-Waldrip T, Meir M, Fan D, et al. The role of gut microbiota in the development of intestinal GVHD. Biol Blood Marrow Transplant 2014; 20: 55-6. [CrossRef]
- Tanaka M, Kobayashi s, Numata A, et al. The impact of the dose of natural killer cells in the graft on severe acute graftversus- host disease after unrelated bone marrow transplantation. Leuk Res 2012; 36: 699-703. [CrossRef]
- Andermann T, Peled J, Ho C, et al. Microbiome-Host Interactions in Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant 2018; 24: 1322-40. [CrossRef]
- Staffas A, Silva MB, MR Brink VD. The intestinal microbiota in allogeneic hematopoietic transplant and graft-versus-host-disease. Blood 2017; 129: 927-33. [CrossRef]
- Rodriguez-Otero P, Porcher R, Peffault de Latour R, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 2012; 119: 5909-17. [CrossRef]
- Klein SA, Martin H, Schreiber-Dietrich D, et al. A new approach to evaluating intestinal acute graft-versus-host disease by transabdominal sonography and colour Doppler imaging. Br J Haematol 2001; 115: 929-34. [CrossRef]
- Neumann S, Schoppmeyer K, Lange T, et al. Wireless capsule endoscopy for diagnosis of acute intestinal graft-versushost disease. Gastrointest Endosc 2007; 65: 403-9. [CrossRef]
- Shulman HM, Cardona DM, Greenson JK, et al. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease, II: the 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015; 21: 589-603. [CrossRef]
- Kreft A, Mottok A, Mesteri I, et al. Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. Virchows Arch 2015; 467: 255-63. [CrossRef]
- Changqing MA, Horacio M, Ta-Chiang L. Acute graft-versus host disease is more prevalent and severe in lower than the upper gastrointestinal tract. Human Pathol 2015; 46: 1480-7. [CrossRef]
- Mielcarek M, Furlong T, Storer BE, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graftversushost disease: a randomized controlled trial. Haematologica 2015; 100: 842-8. [CrossRef]
- Bolan˜os-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014; 124: 3221-7. [CrossRef]
- Rager A, Frey N, Goldstein SC, et al. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow Transplant 2011; 46: 430-5. [CrossRef]
- Schub N, Gunther A, Schrauder A, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011; 46: 143-7. [CrossRef]
- Bilgin AU, Topcuoglu P, Sancak T, et al. Intramesenteric Steoid Treatment for Steroid-Refractory Gastrointestinal Graft Versus Host Disease. Turk J Haematol 2012; 29: 409-12. [CrossRef]
- Martin P, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommenda tions of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-63. [CrossRef]
- Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia 2015; 29: 2062-8. [CrossRef]
- Dotoli GM, Santis GCD, Orellana MD, et al. Mesenchymal stromal cell infusion to treat steroid refractory acute GVHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 52: 859-62. [CrossRef]
- Ali SA, Shah V, Mckinnon R, Van harn M, Janakiraman N. Frequent expression of C4d in hepatic graft-versus hostdisease: potential clue for diagnosis and distinguishing acute and chronic form. Transpl Immunol 2010; 23: 77-80. [CrossRef]
- Pan B, Zhang Y, Sun Y, et al. Deviated balance between Th1 and Th17 cells exacerbates acute graft-versus-host disease in mice. Cytokine 2014; 68: 69-75. [CrossRef]
- Vierling Jm, Hreha G, Wang H, Braun M. The role of biliary epithelial cells in the immunopathogenesis of nonsuppurative destructive cholangitis in murine hepatic graft-versus-host disease. Trans Am Clin Climatol Assoc 2011; 122: 326-35.
- Song Mk, Chung Js, Kim S, et al. Hepatic artery resistance index at Doppler ultrasonography is a useful parameter of hepatic graftvs-host disease after allogeneic stem cell transplantation. Transplant Proc 2010; 42: 3717-22. [CrossRef]
- Demirer T, Petersen FB, Bensinger WI, et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplantation 1996; 18: 29-34.
- Carreras E, Fernandez-Aviles F, Silva L, Guerrero M, Fernandez de Larrea C, Martinez C. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant 2010; 45: 1417-22. [CrossRef]
- Chang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant 2014; 20: 1407-17. [CrossRef]
- Cornell RF, Hari P, Zhang MJ, et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1368-73. [CrossRef]
- Coppell JA, Richardson PG, Soiffer R, et al. Hepatic venoocclusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157- 68. [CrossRef]
- Fan CQ, Crawford JM. Sinusoidal Obstruction Syndrome. J Clin Exp Hepatol 2014; 4: 332-46. [CrossRef]
- Kroger N, Damon L, Zander AR, et al. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients Group Author(s): European Grp Blood Marrow Translpl; German Adjuvant Breast Canc Study; Univ California San Francisco. Bone Marrow Transplant 2003; 32: 1153-7. [CrossRef]
- Vion AC, Rautou PE, Durand F, Boulanger CM, Valla DC. Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: focus on hepatic veno-occlusive disease. Semin Thromb Hemost 2015; 41: 629-43. [CrossRef]
- De Giorgi U, Rosti G, Slavin S, et al. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumors. Br J Cancer 2005; 93: 412-7. [CrossRef]
- De Giorgi U, Demirer T, Wandt H, et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol 2005; 16: 146-51. [CrossRef]
- Demirer T, Celebi H, Arat M, et al. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 335-7. [CrossRef]
- Chao N. How I treat sinusoidal obstruction syndrome. Blood 2014; 123: 4023-6. [CrossRef]
- Brunvand MW, Bensinger WI, Soll E, et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant 1996; 18: 131-41.
- Demirer T, Buckner CD, Petersen FB, et al. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995; 15: 915-22.
- Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003: 78: 589-98. [CrossRef]
- Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996; 17: 341-6.
- Ayash LJ, Hunt M, Antman K, et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699-706. [CrossRef]
- Demirer T, Gooley T, Buckner CD et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplant 1995; 15: 907-13.
- Dignan FL, Wynn RF, Hadzic N, Karani J, et al. BCSH/BSMT guideline:diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following hematopoietic stem cell transplantation. Br J Hematol 2013; 163: 444-57. [CrossRef]
- Lee JH, Lee KH, Lee JH, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic venoocclusive disease after allogeneic bone marrow transplantation in adults conditioned with busulfan and cyclophosphamide. Br J Haematol 2002; 118: 1087-94. [CrossRef]
- Cutler C, Kim HT, Ayanian S, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 2010; 16: 1180-5. [CrossRef]
- Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-9. [CrossRef]
- Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 497-506. [CrossRef]
- Corbacioglu S, Carreras E, Mohty M, et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results from the International Compassionate-Use Program. Biol Blood Marrow Transplant 2016; 22: 1874-82. [CrossRef]
- Van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinjé J, Koopmans MP, Rozenberg-Arska M. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2000; 26: 299-303. [CrossRef]
- Pala C, Kaynar L, Buyukoglan R, et al. Diarrhea in peripheral stem cell transplant recipients: a developing country’s experience. J Infect Dev Ctries 2014; 8: 635-41. [CrossRef]
- Bhutani D, Dyson G, Manasa R, et al. Incidence, Risk Factors and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft vs Host Disease. Biol Blood Marrow Transplant 2015; 21: 159-64. [CrossRef]
- Spadao F, Gerhard, Guimaraes T, et al. Incidence of Diarrhea by Clostridium Difficile in Hematologic Patients and Hematopoietic Stem Cell Tranplantation Patients: Risk Factor for Severe Forms and Death. Rev Inst Med Trop Sao Paulo 2014; 56: 325-33. [CrossRef]
- Lee YJ, Arguello ES, Jenq RR, et al. Protective Factors in the Intestinal Microbiome Against Clostridium dificile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. J Infect Dis 2017; 215: 1117-23. [CrossRef]
| APA | ATİLLA E, ATACA ATİLLA P, CENGİZ SEVAL G, BEKTAŞ M, DEMİRER T (2019). Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. , 122 - 131. |
| Chicago | ATİLLA Erden,ATACA ATİLLA Pınar,CENGİZ SEVAL GÜLDANE,BEKTAŞ Mehmet,DEMİRER Taner Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. (2019): 122 - 131. |
| MLA | ATİLLA Erden,ATACA ATİLLA Pınar,CENGİZ SEVAL GÜLDANE,BEKTAŞ Mehmet,DEMİRER Taner Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. , 2019, ss.122 - 131. |
| AMA | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. . 2019; 122 - 131. |
| Vancouver | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. . 2019; 122 - 131. |
| IEEE | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T "Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation." , ss.122 - 131, 2019. |
| ISNAD | ATİLLA, Erden vd. "Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation". (2019), 122-131. |
| APA | ATİLLA E, ATACA ATİLLA P, CENGİZ SEVAL G, BEKTAŞ M, DEMİRER T (2019). Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology, 30(2), 122 - 131. |
| Chicago | ATİLLA Erden,ATACA ATİLLA Pınar,CENGİZ SEVAL GÜLDANE,BEKTAŞ Mehmet,DEMİRER Taner Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology 30, no.2 (2019): 122 - 131. |
| MLA | ATİLLA Erden,ATACA ATİLLA Pınar,CENGİZ SEVAL GÜLDANE,BEKTAŞ Mehmet,DEMİRER Taner Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology, vol.30, no.2, 2019, ss.122 - 131. |
| AMA | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology. 2019; 30(2): 122 - 131. |
| Vancouver | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Turkish Journal of Gastroenterology. 2019; 30(2): 122 - 131. |
| IEEE | ATİLLA E,ATACA ATİLLA P,CENGİZ SEVAL G,BEKTAŞ M,DEMİRER T "Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation." Turkish Journal of Gastroenterology, 30, ss.122 - 131, 2019. |
| ISNAD | ATİLLA, Erden vd. "Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation". Turkish Journal of Gastroenterology 30/2 (2019), 122-131. |
